Can chronic inflammation raise hepcidin and cause functional iron deficiency even with normal hemoglobin?

The physiological link between chronic inflammation and iron metabolism is well-documented, describing a state known as functional iron deficiency (FID) or iron-restricted erythropoiesis. This process occurs even in the absence of clinical anemia, where hemoglobin levels remain within the standard reference range.

Mechanistic pathway: The IL-6/Hepcidin axis

Chronic inflammation initiates a signaling cascade that directly alters iron distribution.

• Hepcidin upregulation: Pro-inflammatory cytokines, most notably Interleukin-6 (IL-6), trigger the JAK2/STAT3 signaling pathway in hepatocytes. This leads to the increased transcription of the HAMP gene, which encodes hepcidin, the master regulator of systemic iron.
• Ferroportin degradation: Hepcidin acts as a negative regulator by binding to ferroportin (Fpn), the only known cellular iron exporter. Upon binding, hepcidin induces the internalization and lysosomal degradation of ferroportin.
• Iron sequestration: With fewer ferroportin channels available, iron becomes trapped within macrophages (which recycle iron from old red cells) and duodenal enterocytes (which absorb dietary iron). This effectively "locks" iron in storage, preventing its release into the plasma.

Clinical evidence and functional iron availability

This sequestration creates a paradox where total body iron stores may be high, but the iron is unavailable for biological processes.

• Functional Iron Deficiency (FID): FID is characterized by a Transferrin Saturation (TSAT) of <20%, indicating that the circulating iron supply is insufficient to meet the demands of the bone marrow, despite normal or even elevated ferritin levels (often >100 ng/mL in inflammatory states).
• Pre-anemic states: Research confirms that iron-restricted erythropoiesis can persist for extended periods while hemoglobin remains >12.0 g/dL (in females) or >13.0 g/dL (in males). In these cases, the body maintains hemoglobin by drawing down every available bit of functional iron, but at the cost of reduced enzyme function and cellular energy metabolism in other tissues.
• Early markers: Indicators such as reticulocyte hemoglobin content (Ret-Hb) and soluble transferrin receptor (sTfR) levels often show abnormalities before a drop in hemoglobin occurs, serving as sensitive markers for iron restricted by inflammation.

Clinical implications

For patients with chronic inflammatory conditions—such as autoimmune disorders, chronic kidney disease, or obesity-related inflammation—standard anemia screening (hemoglobin/hematocrit) may fail to detect significant iron-related dysfunction.

• Symptomatology: Individuals with FID often report fatigue, reduced exercise tolerance, and cognitive "fog" even when hemoglobin is normal, as iron is a necessary cofactor for mitochondrial function and neurotransmitter synthesis.
• Diagnostic nuance: In the context of inflammation, ferritin acts as an acute-phase reactant; therefore, a "normal" ferritin level (e.g., 50–100 ng/mL) may actually mask a true underlying deficiency in the presence of high hepcidin.

Bottom line

Chronic inflammation effectively "starves" the blood of iron by increasing hepcidin, which degrades the exporters necessary to move iron out of storage. This creates a state of functional iron deficiency that can significantly impact health and energy levels well before hemoglobin drops into the anemic range.